New Delhi : Orchid Pharma has received the Establishment inspection report (EIR) from the US health regulator based on the successful inspection closure for its API manufacturing facility in Tamil Nadu’s Kancheepuram district.
“Orchid received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing facility located at Alathur, Kancheepuram district. The facility was inspected by USFDA in the month of August 2015,” the company said in a BSE filing today.
USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
Shares of Orchid Pharma were trading 6.84 per cent up at Rs 41.40 a piece on BSE.